Peripheral Artery Disease and Risk of Kidney Outcomes: The Atherosclerosis Risk in Communities (ARIC) Study

Overview

Journal Atherosclerosis

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2024 Sep 14

PMID 39276420

Authors

Amy Paskiewicz

Frances M Wang

Junichi Ishigami

Yuanjie Pang

Yingying Sang

Shoshana H Ballew

Morgan E Grams

Gerardo Heiss

Josef Coresh

Kunihiro Matsushita

Affiliations

Soon will be listed here.

Abstract

Background And Aims: The potential impact of peripheral artery disease (PAD) on kidney outcomes is not well understood. The aim of this study was to explore the association between PAD and end-stage kidney disease (ESKD) and chronic kidney disease (CKD).

Methods: Among 14,051 participants (mean age 54 [SD 6 years]) from the Atherosclerosis Risk in Communities study, we categorized PAD status as symptomatic PAD (intermittent claudication or leg revascularization), asymptomatic PAD (ankle-brachial index [ABI] ≤0.90 without clinical history of symptoms), and ABI 0.91-1.00, 1.01-1.10, 1.11-1.20 (reference), 1.21-1.30, and >1.30. We evaluated their associations with two kidney outcomes: ESKD (the need of renal replacement therapy or death due to kidney disease) and CKD (ESKD cases or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m with a ≥25 % decline from the baseline) using multivariable Cox proportional hazards models.

Results: Over ∼30 years of follow-up, there were 598 cases of incident ESKD and 4686 cases of incident CKD. After adjusting for potential confounders, both symptomatic PAD and asymptomatic PAD conferred a significantly elevated risk of ESKD (hazard ratio 2.28 [95 % confidence interval 1.23-4.22] and 1.75 [1.19-2.57], respectively). Corresponding estimates for CKD were 1.54 (1.14-2.09) and 1.63 (1.38-1.93). Borderline low ABI 0.91-1.00 also showed elevated risk of adverse kidney outcomes after adjustment for demographic variables. Largely consistent results were observed across demographic and clinical subgroups.

Conclusions: Symptomatic PAD and asymptomatic PAD were independently associated with an elevated risk of ESKD and CKD. These results highlight the importance of monitoring kidney function in persons with PAD, even when symptoms are absent.

References

Beckman J, Duncan M, Damrauer S, Wells Q, Barnett J, Wasserman D . Microvascular Disease, Peripheral Artery Disease, and Amputation. Circulation. 2019; 140(6):449-458. PMC: 6682431. DOI: 10.1161/CIRCULATIONAHA.119.040672. View

Heerspink H, Kosiborod M, Inzucchi S, Cherney D . Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018; 94(1):26-39. DOI: 10.1016/j.kint.2017.12.027. View

Gupta R, Assiri S, Cooper C . Renal Artery Stenosis: New Findings from the CORAL Trial. Curr Cardiol Rep. 2017; 19(9):75. DOI: 10.1007/s11886-017-0894-2. View

Huang R, Fu P, Ma L . Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduct Target Ther. 2023; 8(1):129. PMC: 10023808. DOI: 10.1038/s41392-023-01379-7. View

Casas J, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani A . Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005; 366(9502):2026-33. DOI: 10.1016/S0140-6736(05)67814-2. View

Berger J, Ladapo J . Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2017; 69(18):2293-2300. PMC: 5497594. DOI: 10.1016/j.jacc.2017.02.064. View

Gutierrez J, Aday A, Patel M, Jones W . Polyvascular Disease: Reappraisal of the Current Clinical Landscape. Circ Cardiovasc Interv. 2019; 12(12):e007385. PMC: 7660526. DOI: 10.1161/CIRCINTERVENTIONS.119.007385. View

ROSE G . The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962; 27:645-58. PMC: 2555832. View

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 73(24):3168-3209. DOI: 10.1016/j.jacc.2018.11.002. View

10.

Weatherley B, Chambless L, Heiss G, Catellier D, Ellison C . The reliability of the ankle-brachial index in the Atherosclerosis Risk in Communities (ARIC) study and the NHLBI Family Heart Study (FHS). BMC Cardiovasc Disord. 2006; 6:7. PMC: 1435775. DOI: 10.1186/1471-2261-6-7. View

11.

Golestaneh L, Alvarez P, Reaven N, Funk S, McGaughey K, Romero A . All-cause costs increase exponentially with increased chronic kidney disease stage. Am J Manag Care. 2017; 23(10 Suppl):S163-S172. View

12.

Selvin E, Wattanakit K, Steffes M, Coresh J, Sharrett A . HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2006; 29(4):877-82. DOI: 10.2337/diacare.29.04.06.dc05-2018. View

13.

Poredos P, Cifkova R, Maier J, Nemcsik J, Sabovic M, Jug B . Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. Atherosclerosis. 2022; 348:25-35. DOI: 10.1016/j.atherosclerosis.2022.03.030. View

14.

Sonoda H, Nakamura K, Tamakoshi A . Ankle-Brachial Index is a Predictor of Future Incident Chronic Kidney Disease in a General Japanese Population. J Atheroscler Thromb. 2019; 26(12):1054-1061. PMC: 6927805. DOI: 10.5551/jat.47779. View

15.

. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989; 129(4):687-702. View

16.

Liao D, Arnett D, Tyroler H, RILEY W, Chambless L, Szklo M . Arterial stiffness and the development of hypertension. The ARIC study. Hypertension. 1999; 34(2):201-6. DOI: 10.1161/01.hyp.34.2.201. View

17.

Murray G, Butcher I, Heald C, Lee R, Chambless L, Folsom A . Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008; 300(2):197-208. PMC: 2932628. DOI: 10.1001/jama.300.2.197. View

18.

Wu A, Coresh J, Selvin E, Tanaka H, Heiss G, Hirsch A . Lower Extremity Peripheral Artery Disease and Quality of Life Among Older Individuals in the Community. J Am Heart Assoc. 2017; 6(1). PMC: 5523635. DOI: 10.1161/JAHA.116.004519. View

19.

Brevetti G, Giugliano G, Brevetti L, Hiatt W . Inflammation in peripheral artery disease. Circulation. 2010; 122(18):1862-75. DOI: 10.1161/CIRCULATIONAHA.109.918417. View

20.

Alcazar J, Rodicio J . Ischemic nephropathy: clinical characteristics and treatment. Am J Kidney Dis. 2000; 36(5):883-93. DOI: 10.1053/ajkd.2000.19077. View